Commenting on the collaboration and state-of-the-art facility, Mr Darling said: "This new centre is right at the forefront of the fight against some of the major diseases in the world. It means a world leading facility based here in the UK bringing the best of industry and academia together backed by the Government. It will give researchers what they need to enhance our reputation as a world leader in science, research and putting great ideas into practice, speeding up the process to deliver the new medicines that patients need."
GSK's CIC is a unique venture undertaken by GSK, Imperial College London and the Medical Research Council - the largest new imaging centre in Europe dedicated to development and application of imaging techniques for clinical research. The collaboration will combine the expertise and knowledge each partner has developed in the use of imaging technologies and will apply it to the development of new medicines across a broad range of diseases including cancer, cardiovascular disease, and psychiatric and neurological disorders. One of the world's largest industry-university-government collaborations, the CIC will create a globally-recognised centre of expertise in West London and substantially increase the entire research base in medical imaging in the UK.
"GSK's investment in this state-of-the-art research facility reflects the positive environment for science and innovation in the UK. The science we conduct here will transform the lives of patients in the UK and around the world. It is important to us, and to the UK, that the environment remains supportive" said Dr Moncef Slaoui, Chairman, GlaxoSmithKline Research & Development. "This facility will allow GSK to partner with Imperial College and the MRC to create a world-class scientific collaboration, utilising the latest advancements in imaging to better understand diseases and how to treat them."
Sir Richard Sykes, Rector of Imperial College London, said, "This centre is a prime example of what can be achieved when universities, government and industry work side by side. It enables us to translate our scientific advances into improving patient care as quickly as possible. By combining the expertise of leaders in imaging technology and giving them access to the very latest equipment, we can advance our understanding of diseases that affect millions of people."
The CIC building, which is adjacent to the Hammersmith Hospital site of Imperial College London, was carefully selected for the new development as it is already home to many of the world's leading experts in imaging technology.
"The CIC is located at the heart of a clinical research centre comprising the MRC's Clinical Sciences Centre, Imperial College and Hammersmith Hospital and will benefit from the dynamism which prevails there," said Professor Colin Blakemore, Chief Executive of the Medical Research Council. "It has been an eagerly awaited addition to the site, providing substantial additional resources to a group of clinicians and scientists buzzing with ideas on how to make the most of such equipment and facilities both academically and to the benefit of patients. Imaging is allowing us to go further than many of us had imagined possible in understanding how the human body works and is an area which will greatly inform therapeutic interventions and drug development in the years to come."
Modern imaging technology provides a 'window' through which to study in fine detail both disease processes and the action of potential medicines in human organs such as the brain, heart and lungs - disease-associated changes in glucose metabolism, for example, or the affinity of the drug for its target. Its sensitivity allows molecular interactions to be probed.
Backed by a 10 year commitment by GSK to invest £11 million a year in this centre, the CIC will use and advance the latest technologies in magnetic resonance imaging (MRI) and positron emission tomography (PET). Its facilities include an advanced radiochemistry development facility, two MRI machines and two PET scanners which give the unit the capacity to conduct up to 2500 scans annually. Built over 3 floors it will be staffed by almost 80 clinical, scientific and support staff, plus an additional eight Research Fellows from Imperial College.
The whole Burlington Danes centre, which encompasses the GSK CIC, ICL and MRC facilities, will eventually employ around 400 researchers and support staff. Around half of these will be new positions. In addition to the research centre, the completed development will include affordable housing for over 300 health workers, provided by the Charity Trustees for Hammersmith Hospital's partner Thames Valley Housing Association.
Staphylococcus aureus: A new mechanism involved in virulence and antibiotic resistance
23.03.2018 | Institut Pasteur
Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Materials Sciences
23.03.2018 | Agricultural and Forestry Science
23.03.2018 | Physics and Astronomy